Last reviewed · How we verify
decompensated cirrhosis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Livdelzi | SELADELPAR | Gilead Sciences Inc | 2026-01-01 | |||
| Iqirvo | ELAFIBRANOR | Ipsen | Peroxisome Proliferator-activated Receptor Agonist [EPC] | 2024-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Gilead Sciences Inc · 1 drug in decompensated cirrhosis
- Ipsen · 1 drug in decompensated cirrhosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in decompensated cirrhosis:
- decompensated cirrhosis treatment updates — RSS
- decompensated cirrhosis treatment updates — Atom
- decompensated cirrhosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). decompensated cirrhosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/decompensated-cirrhosis. Accessed 2026-06-10.
Related
- decompensated cirrhosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing